Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

MEGACD40L® Protein (soluble) (human), (recombinant)

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
ALX-522-110-C010 10 µg 499.00 USD
Do you need bulk/larger quantities?
  • Highly active MEGACD40L® oligomer mimics in vivo membrane-assisted CD40L aggregation and stimulation without the need for enhancers
  • High purity with low endotoxin levels
  • Experienced manufacturing results in consistent and dependable lot-to-lot performance
  • Optimized formulation for improved stability and enhanced activity
MEGACD40L® is a high activity protein in which two trimeric CD40 ligand molecules are artificially linked via the collagen domain of Adiponectin/ACRP30/AdipoQ. This protein very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo. It provides a simple and equally potent alternative to [CD40L+enhancer] combinations (Prod. No. ALX-850-064).

Product Specification

Alternative Name:CD40L:ACRP30headless, CD154:ACRP30headless, TNFSF 5:ACRP30headless, gp39:ACRP30headless
Source:Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
UniProt ID:P29965 (human CD40L), Q60994 (mouse Adiponectin)
Concentration:0.1mg/ml after reconstitution.
Formulation:Lyophilized. Contains PBS.
Purity:≥90% (SDS-PAGE)
Purity Detail:Purified by multi-step chromatography.
Endotoxin Content:≤0.01EU/µg purified protein (LAL test; Cape Cod Associates).
Biological Activity:Binds to human CD40. Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86).
Application Notes:Can be used to mediate immune and inflammatory responses, as a protein tool for pre-clinical studies in immunotherapy, to monitor patients undergoing chemotherapy and to mimic autoimmune phenotypes in vivo.
Reconstitution:Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
Shipping:Shipped on Blue Ice
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Technical Info/Product Notes:FLAG is a registered trademark of Sigma-Aldrich Co.
ALX-522-110 Fig1
Graphical representation of MEGACD40L®, Soluble (human) (recombinant) (Prod. No. ALX-522-110).
ALX-522-110 Fig6
PBMCs (peripheral blood mononuclear cells) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells per well) containing 200µl serum free test media with serially diluted MEGACD40L® (Prod. No. ALX-522-110), CD40L (Prod. No. ALX-522-015), or CD40L + 2µg/ml Enhancer (Prod. No. ALX-804-034). After treatment the cells were washed 3X with PBS + 1% BSA. The cells were dual stained for 2 hours at 4°C with mouse anti-human CD19 (PE conjugate) and mouse anti-human CD86 (APC conjugate). The cells were washed 2X with PBS + 1% BSA, then re-suspended In PBS. Samples were analyzed on a BD Facs Calibur flow cytometer. The data is presented as the percent of CD86 positive cells per CD19 positive B cells at each concentration.
ALX-522-110 Fig5
MEGACD40L® was subjected to stability testing by storing the protein at the indicated temperature for 2 months. The protein was then tested for activity using a B cell activation assay. Results indicate MEGACD40L® retains activity under even harsh storage conditions.
ALX-522-110 Fig4
MEGACD40L® from 7 consecutive manufacturing lots was tested using a B-cell activation assay at 1000ng/mL.
ALX-522-110 Fig3
B cell lymphocyte activation by MEGACD40L® (Prod. No. ALX-522-110). Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells/well). Each well contained 200µl serum free test media with serially diluted MEGACD40L®. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of MEGACD40L®.
Please mouse over
ALX-522-110 Fig1 ALX-522-110 Fig6 ALX-522-110 Fig5 ALX-522-110 Fig4 ALX-522-110 Fig3

Product Literature References

Artesunate shows potent anti-tumor activity in B-cell lymphoma: T. K. Vatsveen, et al.; J. Hematol. Oncol. 11, 23 (2018), Abstract; Full Text
CD40L and TNF both activate the classical NF-κB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells: J. Seigner, et al.; Biochem. Biophys. Res. Commun. 495, 1389 (2018), Abstract;
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma: H. Rauert-Wunderlich, et al.; Cell Death Dis. 9, 86 (2018), Abstract; Full Text
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus: J.M. Riggs, et al.; Lupus Sci. Med. 5, (2018), Abstract; Full Text
High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation: A.F. Zahorchak, et al.; Cell. Immunol. 323, 9 (2018), Abstract;
Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA: O. Dedobbeleer, et al.; J. Immunol. 199, 391 (2017), Abstract; Full Text
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice: V.A. Carroll, et al.; PNAS 113, 13168 (2016), Application(s): Human B cells culture, Abstract; Full Text
T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity: P. Szodoray, et al.; J. Allergy Clin. Immunol. 138, 839 (2016), Application(s): Cell culture, Abstract;
A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia: S. van den Berg, et al.; Int. J. Med. Microbiol. 305, 55 (2015), Application(s): ELISA, PCR of human blood samples, Abstract;
CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity: C. Zaccard, et al.; J. Immunol. 194, 1047 (2015), Application(s): Activation of mature human dendritic cells, Abstract;
Phenotypic Approaches to Identify Inhibitors of B Cell Activation: E. B. Rex, et al.; J. Biomol. Screen. 20, 876 (2015), Application(s): Assay, Abstract; Full Text
A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo: N. Lewis, et al.; PLoS One 9, e100883 (2014), Application(s): Assay of human PBMC, Abstract; Full Text
Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential: D. Ito, et al.; Leuk. Lymphoma 56, 219 (2014), Application(s): Analysis of canine B-cell lymphoma cells, Abstract;
Exosomes Derived from Burkitt’s Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch Recombination in B Cells: C. Gutzeit, et al.; J. Immunol. 192, 5852 (2014), Application(s): PCR, Assay of human B cells, Abstract; Full Text
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study: C. London, et al.; PLoS One 9, e87585 (2014), Application(s): Analysis of canine tumor cells by WB, FLOW, Abstract; Full Text
Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).: R. Douglas, et al.; Trans. Am. Ophthalmol. Soc. 12, 26 (2014), Application(s): In vitro analysis of human fibrocytes, Abstract; Full Text
AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling: K.C. Carroll, et al.; J. Leukoc. Biol. 94, 1113 (2013), Abstract;
Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency: F. Mazerolles, et al.; J. Allergy Clin. Immunol. 131, 1146 (2013), Application(s): Assay of blood cells, Abstract;
CD40 ligand is necessary and suffi cient to support primary diff use large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies: D. Ito, et al.; Leuk. Lymphoma 53, 1390 (2012), Application(s): Flow cytometry of human B cells, Abstract; Full Text
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells: N.P. Chung, et al.; J. Immunol. 189, 5257 (2012), Application(s): Activation of dendritic cells, Abstract; Full Text
Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency: B. Boisson, et al.; Nat. Immunol. 13, 1178 (2012), Application(s): ELISA of human blood cells, Abstract; Full Text
Interleukin-6 Production in CD40-Engaged Fibrocytes in Thyroid-Associated Ophthalmopathy: Involvement of Akt and NF-κB: E.F. Gillespie, et al.; Invest. Ophthalmol. Vis. Sci. 53, 7746 (2012), Application(s): CD40 ligation, induction and signaling in Graves' orbital fibroblasts (GOFB) and fibrocytes, Abstract; Full Text
Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts: F. Gieseke, et al.; Eur. J. Immunol. 42, 2176 (2012), Application(s): ELISA of human B cells , Abstract; Full Text
New mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency: impairment of ubiquitin binding despite normal folding of NEMO protein: M. Hubeau, et al.; Blood 118, 926 (2011), Abstract;
Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation: A. Harui, et al.; J. Neuroimmune Pharmacol. 6, 148 (2011), Application(s): Activation of dendritic cells, Abstract; Full Text
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like Receptor 3 response and susceptibility to Herpes Simplex Encephalitis: R. Perez de Diego, et al.; Immunity 33, 400 (2010), Abstract;
Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus ventors MVA and NYVAC expressing HIV antigens : C.E. Gomez, et al.; Vaccine 27, 3165 (2009), Abstract;
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005), Abstract; Full Text
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003), Abstract; Full Text

Related Products

CD40L, soluble (human) (recombinant) set 

Ligand plus enhancer for improved stability and enhanced immune activation.
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE)., FUNC | Print as PDF
ALX-850-064-KI01 1 Set 515.00 USD
Do you need bulk/larger quantities?

CD40L monoclonal antibody (5F3) 

Flow Cytometry | Print as PDF
ADI-CSA-187-E 100 µg 319.00 USD
Do you need bulk/larger quantities?

CD40L (human) monoclonal antibody (blocking) (MK13A4) 

Flow Cytometry, FUNC | Print as PDF
ALX-805-037-C100 100 µg Purified 297.00 USD
Do you need bulk/larger quantities?

CD40L (soluble) (human), (recombinant) 

Increases the stimulation of B cells
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE), ELISA | Print as PDF
ALX-522-015-C010 10 µg 166.00 USD
ALX-522-015-2010 2x10 µg 226.00 USD
ALX-522-015-6010 6x10 µg SuperPack 554.00 USD
Do you need bulk/larger quantities?

Fc (human):CD40L (soluble) (human), (recombinant) 

Produced in HEK 293 cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to the Fc portion of human IgG1 and a linker peptide (20 aa)., ≥90% (SDS-PAGE), ELISA, FUNC | Print as PDF
ALX-522-076-C010 10 µg 434.00 USD
Do you need bulk/larger quantities?

CD40 polyclonal antibody 

WB | Print as PDF
ADI-CSS-180-D 50 µg 164.00 USD
ADI-CSS-180-F 200 µg 407.00 USD
Do you need bulk/larger quantities?

CD40 (human):Fc (human), (recombinant) 

Produced in HEK 293 cells. The cysteine-rich region (aa 21-193) of human CD40 is fused to the Fc portion of human IgG1., ≥95% (SDS-PAGE), ELISA | Print as PDF
ALX-522-016-C050 50 µg 377.00 USD
Do you need bulk/larger quantities?

CD40 (human):COMP (human), (recombinant) 

First non-antibody blocker of CD40L signalling
Produced in HEK 293 cells. The extracellular domain of human CD40 (aa 1-193) is fused to a FLAG®-tag at the N-terminus and to human cartilage oligomeric matrix protein (COMP, aa 32-80) at the C-terminus., ≥90% (SDS-PAGE) | Print as PDF
ALX-522-064-C010 10 µg 434.00 USD
Do you need bulk/larger quantities?

CD40L, soluble (human) ELISA kit (high sensitivity) 

ELISA | Print as PDF
ALX-850-311-KI01 96 wells 703.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
CD40L Recombinant protein
By catalog section:


Technical Service
Customer Service

Related Literature

Innovative Products to Analyze Immunological Disorders
Innovative Products to Analyze Immunological Disorders
Download as PDF

Product Flyers
True Immune Activation. Highest-Purity MEGACD40L®
True Immune Activation. Highest-Purity MEGACD40L®
Download as PDF

All new literature pieces

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,